Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris: Customer Dialogue Has Changed From Price, Price, Price To Availability

FTC Stepping Up Investigation Into Contracting Practices Of Large GPOs And Wholesalers

Executive Summary

Viatris has weighed in on the FTC’s continued investigations into US healthcare middlemen, arguing that it can be a good thing for an industry battling shortages, even as the firm continues to rationalize products that do not make sense economically.

You may also be interested in...



Viatris Quiet On Generics As Clock Ticks On Value-Add Copaxone Opportunity

Generics Bulletin reviews Viatris’ 2023 financial year, and its prospects ahead of a busy 2024.

FTC, HHS Probe GPO Contracting Practices As Source Of Generic Drug Shortages

Contracting practices and lack of competition among large healthcare group purchasing organizations and drug wholesalers – and their impact on the generic pharmaceutical market – are among topics in request for public comments by the agency.

Viatris: Symbicort Market Shaping ‘Exactly The Way We Thought’

Although transitioning from its generics foundations, Viatris still has interests in certain complex products. The firm spoke about one, its Breyna generic version of Symbicort, at the recent J.P. Morgan Annual Healthcare Conference.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel